Prostate cancer is the most common cancer in men. In the United States in 1998, about 185,000 new cases of prostatic cancer were diagnosed and about 40,000 patients died due to the disease. The prognosis is excellent for patients with localized tumours, however the mean survival for patients with metastatic disease is about 3 years. In the Western countries, about 60% of patients initially diagnosed with prostatic cancer have localized disease. However, in India about 84% of patients diagnosed with prostatic cancer have advanced disease at the time of diagnosis. [1] It is important to note that the majority of men who die of this malignancy are still active and productive members of the society. Today most investigators dealing with this disease feel that healthy men with a life expectancy above 10 years, diagnosed with localized disease, have a potentially curable malignancy and should undergo some form of curative therapy.